• LOGIN
    Login with username and password
Repository logo

BORIS Portal

Bern Open Repository and Information System

  • Publications
  • Projects
  • Funding
  • Research Data
  • Organizations
  • Researchers
  • LOGIN
    Login with username and password
Repository logo
Unibern.ch
  1. Home
  2. Publications
  3. The metabolic and autoregulatory profile of reversible delayed cerebral ischemia in unconscious patients after aneurysmal subarachnoid hemorrhage: a prospective multimodal neuromonitoring cohort study.
 

The metabolic and autoregulatory profile of reversible delayed cerebral ischemia in unconscious patients after aneurysmal subarachnoid hemorrhage: a prospective multimodal neuromonitoring cohort study.

Options
  • Details
BORIS DOI
10.48620/88516
Date of Publication
June 5, 2025
Publication Type
Article
Division/Institute

Clinic of Neurosurger...

Contributor
Veldeman, Michael
Bögli, Stefan Yu
Olakorede, Ihsane
Kastenholz, Nick
Weiss, Miriam
Conzen-Dilger, Catharina
Seyfried, Katharina
Beqiri, Erta
Weyland, Charlotte
Clusmann, Hans
Schubert, Gerrit Alexander
Hoellig, Anke
Smielewski, Peter
Series
Critical Care
ISSN or ISBN (if monograph)
1466-609X
1364-8535
Publisher
BioMed Central
Language
English
Publisher DOI
10.1186/s13054-025-05460-1
PubMed ID
40474300
Uncontrolled Keywords

Cerebral autoregulati...

Cerebral infarction

Cerebral microdialysi...

Delayed cerebral isch...

Perfusion computed to...

Subarachnoid hemorrha...

Description
Background
The detection and treatment of delayed cerebral ischemia (DCI) following aneurysmal subarachnoid hemorrhage (SAH) remain challenging. Multimodal neuromonitoring and CT perfusion scanning (CTP) are promising tools for diagnosing DCI in unconscious patients. This study aims to compare the metabolic and autoregulatory characteristics of patients with cerebral hypoperfusion indicative of DCI that either resolves post-treatment or progresses to infarction due to treatment failure.Methods
In a cohort of 268 consecutive SAH patients, neuromonitoring-comprising intracranial pressure (ICP) and brain tissue oxygen (PtiO2) measurements, and/or cerebral microdialysis-was implemented in 126 (47%) neurologically unassessable patients. Aberrant neuromonitoring measurements triggered CTP, and in cases of confirmed perfusion deficits, first-tier treatment involved induced hypertension. Non-responsive perfusion deficits were further evaluated with conventional angiography, and spasmolysis or angioplasty was performed if suitable vasospasm was identified. DCI-related infarction was noted on CT imaging at discharge, and clinical outcomes were assessed using the modified rankin scale (mRS) at 12 months. Using a generalized linear mixed-effects model (GLMM), factors associated with the occurrence of DCI-related infarction were assessed.Results
CTP deficits were identified in 72 (57%) patients, of whom 63 (88%) had neuromonitoring probes near the affected areas. In 24 patients (38%), perfusion deficits progressed to infarction, while in 39 (62%), deficits were successfully reversed through induced hypertension or spasmolysis. In a GLMM, lower pressure reactivity index (PRx-OR 2.70, 95% CI 1.04-4.67; p < 0.001) and lower lactate-to-pyruvate ratio (LPR-OR 1.02, 95% CI 1.01-1.03; p < 0.001) were independently associated with better treatment response and reduced infarction risk, after adjusting for clinical hemorrhage severity. These effects were observed more than 24 h before cerebral hypoperfusion. Pooled PRx and LPR over this time frame were not associated with functional outcome.Conclusion
Loss of cerebrovascular reactivity and metabolic disturbances precede cerebral hypoperfusion in SAH. Lower PRx and LPR levels are independently associated with improved DCI treatment efficacy. These findings must be interpreted in the context of study limitations, including the small sample size and the focal nature of microdialysis measurements. Nevertheless, the results suggest that invasive neuromonitoring may aid in identifying patients more likely to benefit from treatment.Trial Registration
This project was retrospectivly registered in the German Clinical Trial Register (DRKS00030505) on the third of January 2023.
Handle
https://boris-portal.unibe.ch/handle/20.500.12422/211819
Show full item
File(s)
FileFile TypeFormatSizeLicensePublisher/Copright statementContent
s13054-025-05460-1.pdftextAdobe PDF2.18 MBAttribution (CC BY 4.0)publishedOpen
BORIS Portal
Bern Open Repository and Information System
Build: 960e9e [21.08. 13:49]
Explore
  • Projects
  • Funding
  • Publications
  • Research Data
  • Organizations
  • Researchers
More
  • About BORIS Portal
  • Send Feedback
  • Cookie settings
  • Service Policy
Follow us on
  • Mastodon
  • YouTube
  • LinkedIn
UniBe logo